MENU
TARS
Stock ticker: NASDAQ
PRICE
CHANGE
CAPITALIZATION

Tarsus Pharmaceuticals (TARS) Earnings Date & Reports

Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care... Show more

A.I. Advisor
published Earnings

TARS is expected to report earnings to fall 88.46% to -9 cents per share on March 02

Tarsus Pharmaceuticals TARS Stock Earnings Reports
Q4'26
Est.
$-0.09
Q3'26
Beat
by $0.65
Q2'26
Missed
by $0.21
Q1'26
Beat
by $0.14
Q4'25
Missed
by $0.12
The last earnings report on November 03 showed earnings per share of -77 cents, beating the estimate of -142 cents. With 84.34K shares outstanding, the current market capitalization sits at 3.21B.
A.I.Advisor
Nov 03, 2026

Tarsus Pharmaceuticals (TARS) Q3 2026 Earnings Recap: Record Sales, With a One-Time Charge

Key Takeaways

  • Tarsus Pharmaceuticals (TARS) reported third-quarter 2026 revenue of $194.5 million, up about 64% year over year, exceeding analyst expectations by $3.72 million.
  • GAAP (Generally Accepted Accounting Principles) earnings per share came in at a loss of $14.40, missing estimates by $10.38, driven largely by a one-time acquired in-process research and development (IPR&D) charge.
  • XDEMVY net product sales reached a record $194.6 million, with more than one million bottles dispensed and over $1 billion in cumulative sales since launch.
  • The company raised its full-year 2026 XDEMVY sales guidance to a range of $715 million to $730 million.
  • Gross margin held steady at approximately 93%, and cash, cash equivalents, and marketable securities totaled $309.6 million at quarter end.
  • For additional context on the ticker's Major News, Today's Price Move, Price Targets, and Forecast, explore the dedicated TARS pages.
  • You can also explore Trending AI Robots to see how AI-driven trading strategies are being applied across the market.

Earnings Context and Why It Matters

Tarsus Pharmaceuticals has built one of the fastest-growing commercial franchises in eye care with XDEMVY, the first FDA-approved treatment for Demodex blepharitis, a chronic eyelid condition driven by mite infestation. The company's quarterly revenue has climbed sharply from $17.4 million in fiscal 2023 to $451.4 million in fiscal 2025, powered by expanding prescriber adoption. This quarter's results matter because they test whether that commercial momentum can continue beyond early adopters, while the sizable acquisitions of iRenix and Alkeus reshape the pipeline into the retina market. For investors, the report is a key signal on the durability of XDEMVY demand, the trajectory of direct-to-consumer (DTC) marketing returns, and management's path toward profitability.

Reported Results

Tarsus Pharmaceuticals reported third-quarter 2026 total revenue of $194.5 million, an increase of roughly 64% year over year and ahead of consensus estimates by $3.72 million. The gain was driven by record XDEMVY net product sales of $194.6 million, supported by higher prescription volumes and improved gross-to-net discounts. Gross margin remained approximately 93%.

On the bottom line, the company posted a GAAP net loss of $14.40 per share, which missed analyst expectations by $10.38. The wide loss was primarily attributable to a $632.2 million acquired in-process research and development (IPR&D) expense recognized in connection with the iRenix and Alkeus acquisitions, a non-cash item tied to pipeline expansion rather than the performance of the core commercial business. Cash, cash equivalents, and marketable securities stood at $309.6 million as of September 30, 2026.

Management raised its full-year 2026 XDEMVY sales outlook to between $715 million and $730 million, up from the prior range of $685 million to $705 million, citing stronger patient demand and deeper utilization across prescriber segments.

AI Screener

Tickeron's AI Screener is an AI-powered stock and ETF discovery tool designed to help traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener is built to help identify trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. For investors tracking names like TARS, it offers a structured way to surface new candidates across sectors and refine watchlists.

Market Reaction and Investor Sentiment

Shares of Tarsus Pharmaceuticals traded modestly higher in after-hours trading following the report, with the stock hovering near $73, according to early market data. The market appeared to look past the headline GAAP loss, which was driven by the one-time acquired IPR&D charge, and instead focused on the stronger-than-expected revenue and the upward revision to full-year XDEMVY guidance. Investor sentiment entering the report had been cautious given the expected sequential widening of the loss, but the record product sales and the raise in annual guidance reinforced confidence in the commercial franchise. The key debate for shareholders now centers on whether the spending tied to pipeline expansion and DTC marketing will translate into sustained growth and eventual profitability.

Forward Outlook and Key Factors to Monitor

Management's revised full-year XDEMVY guidance of $715 million to $730 million signals confidence that demand growth will continue through the fourth quarter, even as eye care faces typical seasonal softness from holidays and conferences. Investors will be watching whether weekly prescription trends and refill rates sustain their current trajectory into early 2027.

Profitability remains a central theme. The company has indicated that EBITDA (earnings before interest, taxes, depreciation, and amortization) could turn positive in 2027 if revenue reaches the upper end of expectations while spending stays controlled. The increased research and development commitment, including the expansion into the retina market through the Alkeus and iRenix programs, adds near-term expense but broadens the longer-term pipeline.

Key items to monitor include the pace of gross-to-net discount trends, the return on DTC investment, the progress of the TP-04 program for ocular rosacea, and any updates on international regulatory submissions. These factors will shape how investors evaluate the balance between near-term losses and Tarsus's ambition to build a multi-product eye care franchise.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

Industry Biotechnology

Industry
N/A
Address
15440 Laguna Canyon Road
Phone
+1 949 418-1801
Employees
370
Web
https://www.tarsusrx.com